Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
P

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study

By Insights from 2023 ASH Annual Meeting FEATURING Paolo Ghia
By Insights from 2023 ASH Annual Meeting FEATURING Paolo Ghia
116 views
March 27, 2024

Chapters

Genetic Advantages with Zanubrutinib in 1L CLL

00:00

Broad Efficacy of Zanubrutinib Across CLL Subgroups

02:34

Comments 0
Login to view comments. Click here to Login

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley
Leukemia
05:08

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOI…

Insights from 2023 ASH Annual Meeting

P. Ghia

116 views
06:13

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartin…

Insights from 2023 ASH Annual Meeting

E. Oliva

153 views
20:28

Clinically-Relevant Updates in ALL in Adults

Insights from 2023 ASH Annual Meeting

R. Cassaday

261 views
08:45

The Best of CLL: Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

V. Yazbeck

605 views
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views
21:20

The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequenci…

Insights from 2023 ASH Annual Meeting

J. Watts

179 views
06:43

ASH 2023 Insights: "NPM1-Mutated Myeloid Neoplasms - Outcomes With H…

Insights from 2023 ASH Annual Meeting

G. Montalban Bravo

114 views
09:01

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatinib in…

Insights from 2023 ASH Annual Meeting

J. Cortés

88 views
11:36

ASH 2023 Insights: "Maintenance Rux Is Associated With Low Rates of …

Insights from 2023 ASH Annual Meeting

Z. DeFilipp

32 views
09:09

ASH 2023 Insights: "Venetoclax + Pegcrisantaspase in R/R AML - Overc…

Insights from 2023 ASH Annual Meeting

Y. Liu

60 views
13:15

ASH 2023 Insights: "Bezuclastinib (CGT9486), a Novel KIT D816V TKI, …

Insights from 2023 ASH Annual Meeting

P. Vachhani

49 views
13:07

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Treatme…

Insights from 2023 ASH Annual Meeting

J. Garcia

364 views
06:49

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults …

Insights from 2023 ASH Annual Meeting

M. Luskin

179 views
07:43

ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R/R AL…

Insights from 2023 ASH Annual Meeting

M. Luskin

25 views
04:45

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatment on…

Insights from 2023 ASH Annual Meeting

I. Aldoss

164 views
05:38

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2Ar Acu…

Insights from 2023 ASH Annual Meeting

I. Aldoss

102 views
09:19

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutu…

Insights from 2023 ASH Annual Meeting

M. Fürstenau

61 views
13:31

ASH 2023 Insights: "COVALENT-101 Study - Covalent Menin Inhibitor BM…

Insights from 2023 ASH Annual Meeting

J. Lancet

86 views
01:44

ASH 2023 Insights: "Optimizing Outcomes With Myeloablative Condition…

Insights from 2023 ASH Annual Meeting

C. Oliai

19 views
07:55

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

635 views
10:08

Comparison of Venetoclax Based Treatments for Patients With R/R CLL

Insights from 2023 ASH Annual Meeting

B. Heyman

296 views
18:27

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and …

Insights from 2023 ASH Annual Meeting

H. Erba

208 views
18:01

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Primetim…

Insights from 2023 ASH Annual Meeting

J. Rhodes

329 views
04:21

ASH 2023 Insights: "Improving Long-Term Outcomes With Intensive Indu…

Insights from 2023 ASH Annual Meeting

C. Röllig

135 views
03:03

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib an…

Insights from 2023 ASH Annual Meeting

E. Jabbour

125 views
11:00

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) & Venetoc…

Insights from 2023 ASH Annual Meeting

H. Atluri

29 views
11:02

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone…

Dana-Farber Cancer Institute

M. Luskin

207 views
08:32

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Treatmen…

Insights from 2023 ASH Annual Meeting

D. Yeung

124 views
14:40

ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and Ongoing…

Insights from 2023 ASH Annual Meeting

E. Curran

54 views
14:10

ASH 2023 Insights: "Relapse Incidence Post Unrelated alloSCT With Po…

Insights from 2023 ASH Annual Meeting

A. Nagler

30 views
06:56

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Insights from 2023 ASH Annual Meeting

M. Shadman

824 views
07:04

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patient…

Insights from 2023 ASH Annual Meeting

M. Shadman

408 views
08:11

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or…

Insights from 2023 ASH Annual Meeting

A. Ambinder

50 views
08:26

CLL/SLL Treatment With Post-cBTKi Pirtobrutinib: 30 Months Follow-Up…

Insights from 2023 ASH Annual Meeting

J. Woyach

398 views
06:17

ASH 2023 Insights: "Revumenib Maintenance Therapy Following Revumeni…

Insights from 2023 ASH Annual Meeting

A. Zucenka

71 views
05:12

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Vene…

Insights from 2023 ASH Annual Meeting

N. Shah

410 views
07:06

ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy After …

Insights from 2023 ASH Annual Meeting

N. Ghosh

147 views
08:18

ASH 2023 Insights: "Effect of Ibrutinib Flexible Dosing Strategies o…

Insights from 2023 ASH Annual Meeting

N. Ghosh

101 views
07:22

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme Mali…

Insights from 2023 ASH Annual Meeting

A. Ferrajoli

172 views
09:38

ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & Rituximab…

Insights from 2023 ASH Annual Meeting

C. Chen

31 views
07:18

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Elim…

Insights from 2023 ASH Annual Meeting

K. Rogers

70 views
07:32

ASH 2023 Insights: "Understanding Differential Technologies for Dete…

Insights from 2023 ASH Annual Meeting

J. Cloos

83 views
10:32

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Triple C…

Insights from 2023 ASH Annual Meeting

M. Yilmaz

142 views
07:11

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen…

Insights from 2023 ASH Annual Meeting

M. Amaya

158 views
06:57

TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2n…

Insights from 2023 ASH Annual Meeting

M. Ann Anderson

182 views
05:28

ASH 2023 Insights: "Performance of the Molecular International Progn…

Insights from 2023 ASH Annual Meeting

K. Chien

73 views
10:38

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survi…

Insights from 2023 ASH Annual Meeting

D. Tremblay

37 views